CD8A and neoplasm: T-cell activity evaluated as CD3+ and CD8+ T-lymphocyte density at the tumor center and margins, is a prognostic biomarker in patients with early-stage CRC, which is independent of TNM stage and MSI status for predicting prognosis (38, 39).